Orion Portfolio Solutions LLC Sells 14,132 Shares of Hologic, Inc. (NASDAQ:HOLX)

Orion Portfolio Solutions LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 51,680 shares of the medical equipment provider’s stock after selling 14,132 shares during the period. Orion Portfolio Solutions LLC’s holdings in Hologic were worth $3,726,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Brooklyn Investment Group grew its stake in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the period. Trivant Custom Portfolio Group LLC increased its stake in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 169 shares in the last quarter. UMB Bank n.a. raised its position in shares of Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after purchasing an additional 188 shares during the period. Finally, Capital Investment Counsel Inc boosted its holdings in Hologic by 3.6% in the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Royal Bank of Canada reduced their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Finally, Morgan Stanley reduced their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

NASDAQ:HOLX opened at $61.32 on Monday. The firm has a market capitalization of $13.76 billion, a PE ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The stock’s fifty day moving average is $65.24 and its 200 day moving average is $73.24. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.